In August 2026, economist Nam D. Pham, Ph.D., released research alleging that UnitedHealth Group's actual profitability is significantly higher than its public filings suggest. The study claims the insurer's margins are actually four times larger than reported.
The 33% margin hidden behind pass-through costs
UnitedHealth Group may be significantly overstating its true cost-to-profit ratio by including medical claim payments in its revenue totals. according to the study by economist Nam D. Pham, Ph.D., when pass-through medical costs are excluded from the company's revenue, its operating profit margin averaged 33.0% of gross profit between 2020 and 2025.
This figure stands in stark contrast to the 7.6% average net margin that the health insurance giant publicly claims. The report suggests that UnitedHealth Group obscures its true profitability by counting funds intended to pay medical claims as actual revenue, a practice that differs from how other financial intermediaries, such as brokerage firms, report their income.
A profit profile mirroring top biopharmaceutical manufacturers
The adjusted profit margins for UnitedHealth Group place the insurer in a similar financial tier to the world's leading drug makers. As the August 2026 report details, the 33% margin is comparable to the average seen among the top ten innovative biopharmaceutical manufacturers during the same 2020-2025 period.
The 93% administrative spending vs. 52% R&D divide
While the profit margins of UnitedHealth Group and biopharmaceutical manufacturers may align, their underlying business models remain fundamentally different.. The study highlights that the top ten biopharmaceutical manufacturers reinvested nearly 52% of their operating costs into research and development.
In contrast, UnitedHealth Group operates a low-risk, high-volume model where 93% of operating costs were devoted to selling, general, and administrative expenses. This distinction suggests that while the profit outcomes are similar, the way these companies generate and spend their capital is vastly different.
Will Senate Republicans exploit the 46-point transparency advantage?
The release of this data arrives at a sensitive political moment as President Trump's team urges Senate Republicans to prioritize healthcare in their midterm election messaging. Polling indicates a significant appetite for reform, with Republicans holding a 46-point advantage when campaigning on the need for greater transparency in the health insurance industry.
This transparency push includes scrutiny of insurer profits, rejected claims, and delays in patient care. However, several questions remain: Will UnitedHealth Group challenge the methodology used by Pham to calculate these pass-through costs, and will the Senate move to mandate the specific reporting standards that brokerage firms currently use?
Comments 0